[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fV05T7zgICgwAPVIF2II4Yl7KVE7eDsbUDRvvBikQZtU":8,"$f0tu_lqkNAE0YEQeAQ9i3QromUd6KyItVR_pdZu-UIss":55,"$fYVJeqoQATvZ-rJoRsWOl7ZQC9m3ZhgU6WgA30sSlbsE":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},67364,867287,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","侯信明","聊城市第二人民医院","甲状腺乳腺外科","主治医师",111,0,"乳腺癌 Her-2阳性型：靶向治疗与曲妥珠单抗的全攻略","","https://ystcdn.venuertc.com/venue/AI/fcd72a41-8897-4137-8b4a-a94244473557.jpg","\u003Cdiv id=\"material_title\" class=\"medicine-guide-trastuzu-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌 Her-2阳性型：靶向治疗与曲妥珠单抗的全攻略\u003C/h2>\n\u003C/div>\n\n\u003Cdiv class=\"medicine-guide-trastuzu-summary\">\n  \u003Cp>\n    说到靶向药物，曲妥珠单抗是许多人熟悉的选择之一。作为专门针对HER2蛋白的抗体药物，它在乳腺癌治疗中发挥着重要作用。不过，想要发挥最大疗效，安全用药的细节不能忽视。本文将详细介绍曲妥珠单抗使用时必须掌握的关键要点，包括用法、剂型、用药注意事项、不良反应、储存方法等，让你用药更安心。\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 01 药品主要成分与机制 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg1\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 曲妥珠单抗成分与作用机制 🚩\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cp>\n      曲妥珠单抗（Trastuzumab）是一种人源化单克隆抗体，针对细胞表面的HER2蛋白。通过特异性结合HER2，阻断其介导的信号传导路径，从而抑制细胞的异常增殖，提升靶向疗效。\n    \u003C/p>\n    \u003Cp>\n      该药品通常以注射液的形式供应，规格包括150mg/瓶、440mg/瓶，并配有专用溶媒。药物适合静脉滴注，不能肌肉注射及皮下注射（除非为专用皮下剂型，国内常见为静脉滴注）。\n    \u003C/p>\n    \u003Cp>\n      这一机制确保药物只针对含有过量HER2的细胞，减少对正常细胞的影响。曲妥珠单抗单独使用及与化疗药物联用，能产生协同抑制细胞增殖的效果。\u003Cspan class=\"medicine-guide-trastuzu-note\">（参考文献：Slamon DJ et al., \"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2\", New England Journal of Medicine, 2001）\u003C/span>\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 02 剂型特点与使用技巧 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg2\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 剂型区别与正确使用技巧 🧴\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>静脉注射剂型：\u003C/strong>国内主流为冻干粉针剂，仅能静脉滴注。开瓶后需用专用溶媒稀释，严禁用其它液体替代。所有操作需在无菌条件下完成。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>皮下剂型：\u003C/strong>部分国家上市了皮下注射剂型，但国内尚未普及。若遇皮下剂型，按照说明剂量、部位严格操作。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>用药分享：\u003C/strong>临床遇到一位71岁女性患者，术后按规范静脉注射曲妥珠单抗，疗程中未现严重不适，体现了规范用药的重要性。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>正确做法：\u003C/strong>静脉滴注过程中，每瓶需按医生处方和体重进行剂量核算。滴注速度前半小时缓慢，后续根据患者反应调整，不可自行加快速度。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特殊提醒：\u003C/strong>曲妥珠单抗不能口服，误服无效且易引发肠胃不适。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 03 服药时间与配合方式 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg3\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 用药时间与配伍要求 ⏰\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cp>\n      曲妥珠单抗需定期按疗程静脉注射，常规为每三周一次。但具体间隔需严格遵循医生安排和说明书规定，不得自作主张增减剂量或缩短间隔。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>首次注射：\u003C/strong>建议在医院观察下完成，便于及时处理“输液相关反应”。后续注射如无不适，仍建议在医疗机构完成。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>与其他药物配合：\u003C/strong>曲妥珠单抗常与紫杉类等化疗药物联合，但须遵循严格时间顺序，避免混合滴注。不同药物应分开配制，避免物理或化学不兼容现象。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>食物无直接影响：\u003C/strong>曲妥珠单抗为静脉用药，无需考虑与餐饮时间的关系。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 04 药物相互作用 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg4\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 药物相互作用与风险规避 ⚠️\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>与化疗药物：\u003C/strong>曲妥珠单抗经常与紫杉类（如多西他赛）、蒽环类（如阿霉素）联合。但与蒽环类联用时心脏毒性风险增加。正确做法：有联合需要时，安排心脏功能监测。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>与抗体药物：\u003C/strong>部分治疗方案可与帕妥珠单抗等另一个HER2抗体同时联合。但必须医院安排，勿自行组合。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>与中枢神经系统药物：\u003C/strong>目前研究显示曲妥珠单抗与镇静、抗癫痫药等协同使用时并未有严重药效干扰，但需观察可能的过敏风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>与疫苗：\u003C/strong>治疗期间原则上不建议接种活疫苗，避免免疫抑制或异常反应。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>临床数据：\u003C/strong>多项研究提示曲妥珠单抗与常用化疗药物联合时应避免剂量重复和配制混合，以免引发不良反应。\u003Cspan class=\"medicine-guide-trastuzu-note\">（参考文献：Swain SM et al., \"Cardiac toxicity in patients treated with trastuzumab\", Journal of Clinical Oncology, 2003）\u003C/span>\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 05 用药注意事项和禁忌 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg5\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 禁忌症与重要用药注意事项 🚫\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cp>\n      \u003Cstrong>绝对禁忌：\u003C/strong>\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        对曲妥珠单抗或制剂中任意成分过敏（如既往出现过敏性休克或严重皮疹），绝对禁止使用。\n      \u003C/li>\n      \u003Cli>\n        既往显著心力衰竭、左心室射血分数极低者，不推荐用药。\n      \u003C/li>\n      \u003Cli>\n        妊娠及哺乳期妇女原则上不建议使用，特殊情况须由专科医师决定。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cstrong>用药注意 :\u003C/strong>\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        治疗期间须定期检测心脏功能，包括心脏彩超、心电图，发现功能减退必须暂停用药。\n      \u003C/li>\n      \u003Cli>\n        有高龄、高血压、冠心病史者必须专家会诊后决定剂量。\n      \u003C/li>\n      \u003Cli>\n        肝肾功能不全需调整剂量或延长注射间隔，具体操作应遵医嘱，不可自作主张。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cstrong>重要提醒：\u003C/strong>\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        每次治疗前后观察输液反应，出现寒战、发热、气促需立即告知医护人员。\n      \u003C/li>\n      \u003Cli>\n        切勿随意停药或更改剂量，随访评估结果后才能调整方案。\n      \u003C/li>\n      \u003Cli>\n        未经医生许可，不得合用任何补品或草药，避免不良反应。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 06 常见不良反应与处理方法 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg6\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 曲妥珠单抗常见不良反应及处理方法 👀\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>输液相关反应：\u003C/strong>如寒战、发热、皮疹、呼吸困难。首次治疗应严密观察，如发生立即停药并接受处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>心脏毒性：\u003C/strong>左心室射血分数下降可导致心衰。正确做法：每3个月定期检查心脏，如出现心功能下降即暂停或终止药物。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>血液系统变化：\u003C/strong>一部分人白细胞、血小板略降，但不需特殊干预。若明显降低应检查骨髓及基础血症情况。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>消化道反应：\u003C/strong>如恶心、呕吐、腹泻，可联合对症药物，但严重腹泻需暂停曲妥珠单抗并补液。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>皮肤反应：\u003C/strong>皮疹或瘙痒多能自行缓解。如持续加重需就医。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>临床数据：\u003C/strong>说明书提示，心脏毒性发生率可达4-7%，输液反应主要出现在首次治疗后24小时内。\u003Cspan class=\"medicine-guide-trastuzu-note\">（参考文献：Piccart-Gebhart MJ et al., \"Trastuzumab after Adjuvant Chemotherapy in HER2-positive Breast Cancer\", New England Journal of Medicine, 2005）\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>操作建议：\u003C/strong>任何严重不良反应，请及时通知主治医师，切勿拖延处理。一般反应可对症处理，无需停药。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 07 储存条件与药品有效期 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg7\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存条件与过期药品处理 🧊\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>未开封：\u003C/strong>曲妥珠单抗瓶装应保持2~8℃冷藏，切勿冷冻或高温暴晒。存放于原包装盒中，避免阳光直射。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>开封后：\u003C/strong>干粉剂与溶媒混合后需立即使用，最长保存不超过24小时。混合后超时请弃置，不得再用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过期处理：\u003C/strong>过期曲妥珠单抗不得使用，必须按医疗废物处理规定交由医院或药房回收，不可随意丢弃以免污染环境。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特别提醒：\u003C/strong>药品存放在儿童无法触及的地方。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 08 漏服和过量处理 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg8\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 漏服与过量用药处理方法 🛡️\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>漏服：\u003C/strong>如忘记按时注射曲妥珠单抗，不可自行补打，需尽快联系医生调整计划。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过量：\u003C/strong>目前无大量超剂量相关报道，理论上高剂量易出现心脏毒性及过敏反应。正确做法：出现相关症状及时就医并告知既往用药剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>操作建议：\u003C/strong>不论漏服或过量，千万不可自行操作，均须专业医护处理。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 09 特殊人群用药调整 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg9\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 特殊人群安全用药提醒 👨‍🦳👩‍👧\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>老年患者：\u003C/strong>心脏疾病、肝肾功能减退者，使用前应评估心血管与代谢风险，延长间隔或减少剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>儿童和青少年：\u003C/strong>目前尚无确切安全性和有效性资料，不推荐用于18岁以下。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>妊娠和哺乳期：\u003C/strong>动物实验证实存在胎儿风险，孕期严禁使用。哺乳期服药者需暂停母乳喂养。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 总结与核心提醒 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg10\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">⏳ 全文总结与核心提示\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cp>\n      曲妥珠单抗作为癌症靶向药物，精确作用于HER2蛋白，能够联合多种化疗药品提高预期疗效。但用药安全、规范操作是关键。需要牢记：每次治疗严格按医院方案、注意心脏监测、妊娠哺乳期禁用，不良反应及时就医。储存妥当，开瓶充分使用不过期，漏服和过量立刻专业处理。正确使用曲妥珠单抗，才能充分发挥疗效、降低风险，让治疗更加安心可靠。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 参考文献区域 -->\n\u003Cdiv class=\"medicine-guide-trastuzu-section medicine-guide-trastuzu-bg11\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">📚 参考文献及权威资料\u003C/h2>\n  \u003Cdiv class=\"medicine-guide-trastuzu-content\">\n    \u003Cul>\n      \u003Cli>\n        Slamon DJ, Leyland-Jones B, Shak S, et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. \u003Cem>New England Journal of Medicine\u003C/em>, 344(11), 783-792.\n      \u003C/li>\n      \u003Cli>\n        Swain SM, Whaley FS, Ewer MS. (2003). Cardiac toxicity in patients treated with trastuzumab. \u003Cem>Journal of Clinical Oncology\u003C/em>, 21(3), 485-491.\n      \u003C/li>\n      \u003Cli>\n        Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. (2005). Trastuzumab after Adjuvant Chemotherapy in HER2-positive Breast Cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 353(16), 1659-1672.\n      \u003C/li>\n      \u003Cli>\n        UpToDate. Trastuzumab: Drug Information. Wolters Kluwer, 2024. Accessible at: \u003Ca href=\"https://www.uptodate.com/contents/trastuzumab-drug-information\" target=\"_blank\" class=\"medicine-guide-trastuzu-link\">https://www.uptodate.com/contents/trastuzumab-drug-information\u003C/a>\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.medicine-guide-trastuzu-title {\n  background: linear-gradient(90deg, #e3f0fd 0%, #f8fbff 100%);\n  padding: 32px 26px 20px 26px;\n  border-radius: 12px;\n  box-shadow: 0 4px 12px rgba(87, 164, 255, 0.08);\n  text-align: center;\n  margin-bottom: 28px;\n}\n.medicine-guide-trastuzu-title h1 {\n  font-size: 38px;\n  color: #287edd;\n  letter-spacing: 1px;\n  font-weight: bold;\n  margin: 0;\n}\n.medicine-guide-trastuzu-summary {\n  background: #f4f6fa;\n  border-left: 6px solid #afd8fa;\n  padding: 20px 26px;\n  font-size: 17px;\n  color: #205687;\n  margin-bottom: 32px;\n  border-radius: 9px;\n}\n.medicine-guide-trastuzu-section {\n  margin-bottom: 32px;\n  border-radius: 12px;\n  box-shadow: 0 1px 9px rgba(180, 196, 227, 0.07);\n  overflow: hidden;\n}\n.medicine-guide-trastuzu-bg1 { background: linear-gradient(94deg, #f3f7fa 70%, #e9f5ff 100%);}\n.medicine-guide-trastuzu-bg2 { background: linear-gradient(92deg, #f5fafe 60%, #e4f0fb 100%);}\n.medicine-guide-trastuzu-bg3 { background: linear-gradient(89deg, #f6fafc 54%, #edfaf4 100%);}\n.medicine-guide-trastuzu-bg4 { background: linear-gradient(88deg, #f8fafc 35%, #f1f6ff 100%);}\n.medicine-guide-trastuzu-bg5 { background: linear-gradient(96deg, #f7f8fb 80%, #f3eefa 100%);}\n.medicine-guide-trastuzu-bg6 { background: linear-gradient(92deg, #f4fbfa 60%, #eef7fc 100%);}\n.medicine-guide-trastuzu-bg7 { background: linear-gradient(91deg, #f8f9fa 58%, #f0f7fc 100%);}\n.medicine-guide-trastuzu-bg8 { background: linear-gradient(105deg, #f2f9f8 70%, #f4eeff 100%);}\n.medicine-guide-trastuzu-bg9 { background: linear-gradient(91deg, #f5f9fa 58%, #eaf2fb 100%);}\n.medicine-guide-trastuzu-bg10 { background: linear-gradient(91deg, #f6f9fa 58%, #e9f4fb 100%);}\n.medicine-guide-trastuzu-bg11 { background: linear-gradient(91deg, #f8f9fa 58%, #f5f6fb 100%);}\n.medicine-guide-trastuzu-section h2 {\n  font-size: 28px;\n  font-weight: 600;\n  color: #2253aa;\n  padding: 22px 24px 4px 24px;\n  margin: 0;\n  position: relative;\n  letter-spacing: 0.8px;\n  text-shadow: 0 1px 0 #eaf2fa;\n}\n.medicine-guide-trastuzu-content {\n  padding: 12px 24px 18px 36px;\n  font-size: 17px;\n  color: #375278;\n  line-height: 2;\n  border-radius: 0 0 12px 12px;\n}\n.medicine-guide-trastuzu-content ul {\n  padding-left: 20px;\n  margin-bottom: 8px;\n}\n.medicine-guide-trastuzu-content ul li {\n  margin-bottom: 10px;\n  font-size: 17px;\n}\n.medicine-guide-trastuzu-content strong {\n  color: #205687;\n}\n.medicine-guide-trastuzu-note {\n  color: #7b9ec8;\n  font-size: 16px;\n  margin-left: 4px;\n}\n.medicine-guide-trastuzu-link {\n  color: #287edd;\n  text-decoration: underline;\n  font-size: 15px;\n}\n@media (max-width: 600px) {\n  .medicine-guide-trastuzu-title h1 {font-size: 24px;}\n  .medicine-guide-trastuzu-section h2 {font-size: 18px;}\n  .medicine-guide-trastuzu-content {padding: 11px 12px 15px 12px;}\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"medicine-guide-trastuzu-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80);",547,"2025-09-28 14:38:20","曲妥珠单抗, 乳腺癌, HER2阳性, 靶向治疗, 不良反应, 用药注意事项, 静脉注射, 药物相互作用","本文全面解析乳腺癌HER2阳性型的靶向药物曲妥珠单抗，涵盖用法、剂型、不良反应及注意事项，助力患者安全有效用药。","2025-10-09 07:00:25",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]